期刊文献+

肾移植患者他克莫司血药浓度检测的临床分析 被引量:3

下载PDF
导出
摘要 目的探讨肾移植术后患者他克莫司"治疗窗"浓度及影响因素。方法以58例肾移植患者为研究对象,监测术后他克莫司的血药浓度,不同时间段的血药浓度与性别、年龄等因素的关系。结果他克莫司的血药浓度随术后时间的延长而逐渐降低,术后1个月内同一个体的血药浓度波动范围较大。在同一时间段,不同性别的血药浓度差异无统计学意义(>0.05)。术后6个月老年组的血药浓度均低于青年组和中年组(均<0.05)。结论结合"治疗窗",实施个体化给药,定期检测他克莫司血药浓度,对避免发生药物毒副作用或排斥反应意义重大。
出处 《现代实用医学》 2015年第8期1081-1082,共2页 Modern Practical Medicine
  • 相关文献

参考文献6

  • 1Yokuyama I, Uchida K, Fukao K, et al. FK506: long term study in kidney transplan- tation[J]. Transplant Proc,1995,27(1 ):818-821.
  • 2Mckeon F. When world collide: immuno- suppressants meet protein phosphatases[J]. Cell,1991,66(3):823-826.
  • 3Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-4503A enzymes are respon- sible for biotransformation of FK506 and Rapmycin in man and rat [J]. Drug Metab Dispos,1992,20(5):753-761.
  • 4BosmiiUer C, Ollinger R, Sieb M, et al. Tac- mlimus monotherapy following alemtuzumab in duction in combined kidney-pancreas tran- splantation:results of a prospective randomi- zed lrial [J].Ann Transplant,2012,17(6):45-51.
  • 5于立新,王彦斌,肖露露,付绍杰,叶俊生,李强,王亦斌.肾移植受者术后早期他克莫司用药剂量及浓度个体差异的研究[J].中华泌尿外科杂志,2009,30(3):152-155. 被引量:6
  • 6Balichi I. Clinical study on the application oftacrolimus and DMSO in the treatment of chromic superficial keratitis in dogs[J]. Pol J Vet Sci,2012,15(5):667-676.

二级参考文献11

  • 1王玮,管德林,张小东,马麟麟,陈晓,胡小鹏,赵勇.多药耐药基因多态性与免疫抑制剂应用关系的研究[J].中华泌尿外科杂志,2006,27(S1):89-91. 被引量:3
  • 2张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.细胞色素P450 3A5和多药耐药基因1基因多态性在肾移植患者他克莫司血药浓度监测中的应用[J].肾脏病与透析肾移植杂志,2004,13(4):313-317. 被引量:21
  • 3陈业辉,郑克立,陈立中,戴宇平,费继光,王长希,魏鸿蔼,王良圣,胡建波.口服他克莫司血药浓度-时间曲线下面积[J].中华泌尿外科杂志,2004,25(11):750-752. 被引量:10
  • 4胡永芳,周宏灏.CYP3A4,CYP3A5和MDR1基因多态性对环孢素处置的影响[J].中国药理学通报,2005,21(3):257-261. 被引量:34
  • 5Ferraresso M, Tirelli A, Ghio L, et al. Influence of the CYP3A5 genotype on taerolimus pharmaeokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant, 2007, 11: 296-300.
  • 6Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokineties of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther, 2007, 81: 228-234.
  • 7Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 2002, 12: 451-457.
  • 8Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics, 2008, 18: 339-348.
  • 9Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term taerolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmaeol Ther, 2007, 82: 711-725.
  • 10Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001, 29: 268- 273.

共引文献5

同被引文献20

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部